EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, OLMA: Olema Pharmaceuticals Inc

08 Jan 26 15:59
LAST:

25.58

CHANGE:
 1.49		OPEN:
27.30		HIGH:
27.47		ASK:
0.00		VOLUME:
876.3K
CHG(%):
5.50		PREV:
27.07		LOW:
24.60		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
08 Jan 2626.3226.8624.6025.571.31M
07 Jan 2625.5527.3825.1227.071.74M
06 Jan 2625.0025.2523.8525.041.17M
05 Jan 2625.2825.5624.5125.101.48M
02 Jan 2625.0425.6424.4525.28914.4K
31 Dec 2525.0625.7624.8725.00949.2K
30 Dec 2525.4925.9924.9725.07708.5K
29 Dec 2526.0026.1525.3925.641.1M
26 Dec 2527.4827.6626.1026.23785.6K
24 Dec 2526.9927.8625.8527.451.03M

PROFILE

Name:Olema Pharmaceuticals Inc
About:Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:780 Brannan Street, San Francisco, CA, United States, 94103
Website:https://olema.com
CUSIP:68062P106
CIK:0001750284
ISIN:US68062P1066
FIGI:BBG00T5JMRT4

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-3.83 
Forward P/E:-11.72 
PEG Ratio:0.69 
Price to Book:6.04 
Return on Assets:-0.30 
Return on Equity:-0.50 
EPS Ratio:-1.90 
Shares:80.16M 
Market Cap:2.05B 

TECHNICAL INDICATORS

MA5:25.610.1%
MA10:25.750.6%
MA20:28.5011.4%
MA50:21.6018.4%
MA100:14.9271.5%
MA200:9.74162.5%
STO9:21.81
STO14:7.16 
RSI14:21.04 
WPR14:-90.02 
MTM14:-5.23
ROC14:-0.17 
ATR:1.93 
Week High:27.477.4%
Week Low:23.857.3%
Month High:36.2641.7%
Month Low:23.85162.5%
Year High:36.2641.7%
Year Low:2.86794.4%
Volatility:47.67